Servier Hires Senior Investment Director for Corporate VC Arm

Servier has recruited a new senior investment director for its corporate venture capital arm, according to Global Venturing.

The French pharmaceutical company is adding senior firepower to its venturing operation, a move that signals continued commitment to startup dealmaking despite a difficult funding environment for corporate VC units across Europe.

Servier's corporate VC arm invests from the balance sheet of the parent group, a structure common among European pharmaceutical corporates that prefer evergreen vehicles over closed-end funds. The appointment of a senior investment director typically expands the unit's capacity to source leads, execute transactions and take board seats at portfolio companies.

Global Venturing, the trade publication that first reported the hire, did not disclose the identity of the incoming investment director, the start date or the remit of the new role in its headline announcement.

The move fits a broader pattern. Pharmaceutical groups across Europe have continued to build out corporate venturing teams as they seek early exposure to innovation in drug discovery, medical devices and digital health — areas where traditional business development teams often arrive too late in the cycle.

For Servier, the hire suggests the group intends to keep its venturing operation active on new deals rather than retrenching to manage the existing portfolio. Corporate VC arms across the sector have faced pressure over the past two years as exit markets slowed and parent companies tightened discretionary spending.

The specific investment focus, cheque sizes and reporting lines for the new senior investment director remain subject to confirmation from Servier.

The appointment comes as corporate venturing units across pharma weigh whether to expand into new therapeutic areas or double down on core indications — a decision the new hire will help shape at Servier.